Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma	Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, uveal disorder, uveal melanoma	Recruiting	Phase 3	2026-09-15		NCT07804186

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
IDEAYA Biosciences	12

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cancer Hematology Centers Western Michigan	Grand Rapids	United States	2
Cleveland Clinic	Cleveland	United States	558
Dana Farber Cancer Institute	Boston	United States	300
Duke Cancer Center	Raleigh	United States	1
Honor Health Research Institute	Scottsdale	United States	17
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Northwell Health	New York	United States	13
Princess Margaret Cancer Centre	Toronto	Canada	145
Sarah Cannon Research Institute (SCRI)	Nashville	United States	7
UCLA Medical Center	Los Angeles	United States	4
Universite de Montreal - Centre de Recherche du Centre Hospitalier de l'Universite de Montreal	Montréal	Canada	1
University of Wisconsin Health	Madison	United States	4
Wills Eye Hospital at Thomas Jefferson University	Philadelphia	United States	1